Korean J Helicobacter  Up Gastrointest Res Search

CLOSE


Korean J Helicobacter  Up Gastrointest Res > Volume 18(2); 2018 > Article
The Korean Journal of Helicobacter  and Upper Gastrointestinal Research 2018;18(2):120-126.
DOI: https://doi.org/10.7704/kjhugr.2018.18.2.120    Published online June 10, 2018.
First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study
Moon Won Lee, Gwang Ha Kim  , Sung Yong Han, Young Joo Park, Hye Kyung Jeon, Bong Eun Lee, Geun Am Song
1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. doc0224@pusan.ac.kr
2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Helicobacter pylori 1차 제균 치료: 표준삼제요법과 동시치료법의 후향적 비교분석
이문원1, 김광하1,2, 한성용1, 박영주1, 전혜경1, 이봉은1, 송근암1
부산대학교 의학전문대학원 내과학교실1, 부산대학교병원 의생명연구원2
Correspondence:  Gwang Ha Kim, Tel: +82-51-240-7869, Fax: +82-51-244-8180, 
Email: doc0224@pusan.ac.kr
Received: 23 October 2017   • Revised: 12 December 2017   • Accepted: 15 December 2017
Abstract
BACKGROUND/AIMS
The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70~85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. MATERIALS AND METHODS: Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy. RESULTS: This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001). CONCLUSIONS: Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.
Key Words: Concomitant therapy; Disease eradication; Helicobacter pylori; Standard therapy


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS
FOR REVIEWERS
Editorial Office
Lotte Gold Rose II Room 917, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-565-9946    Fax: +82-2-565-9947    E-mail: hpylori@kams.or.kr                

Copyright © 2022 by Korean College of Helicobacter and Upper Gastrointestinal Research.

Developed in M2PI

Close layer
prev next